latest news releases from the newsroom
KLIPPAN AB -- reduced costs
KLIPPAN, Sweden, Nov. 18, 2003 (PRIMEZONE) -- The work towards lowering costs and reducing losses within KLIPPAN AB is currently considered to be leading to a reduction in staffing levels at the various mills totalling 150 persons. The reduction represents a cost reduction of some MSEK 50. Local negotiations in accordance with the Law on co-determination at work will start shortly at the mills.
Karo Bio Will Consolidate Research Operations to Sweden
HUDDINGE, Sweden, Nov. 18, 2003 (PRIMEZONE) -- Karo Bio has decided to reduce its presence in North Carolina USA. Technologies, key projects and other research activities will be transferred immediately. The consolidated research organization will be located at the Company's headquarters in Huddinge, Sweden. Through this action, Company headcount will be reduced by 26 to reach 100 persons.
Artimplant's Surgical Suture Cleared by FDA
STOCKHOLM, Sweden, Nov. 18, 2003 (PRIMEZONE) -- Artimplant has its first product cleared by FDA. The company's Artelon(TM) Surgical Suture has been approved for marketing in the US. The decision was announced late Monday night.
Trigen Advances Next Generation Anti-Coagulant, Direct Thrombin Inhibitors
LONDON, Nov. 18, 2003 (PRIMEZONE) -- Trigen Ltd today announced that it has successfully identified two novel, competitive clinical candidates from its Direct Thrombin Inhibitor (DTI) programme, which have been codenamed TGN 167 (oral) and TGN 255 (intravenous). Both products offer new approaches for the prevention and treatment of thrombosis. Trigen has initiated a series of additional clinical studies to progress these candidates.
Murray, Frank & Sailer LLP
Rabin Murray & Frank LLP Announces Class Action Lawsuit Against Gilead Sciences, Inc. for Violations of Federal Securities Laws -- GILD
NEW YORK, Nov. 17, 2003 (PRIMEZONE) -- A class action lawsuit has been filed in the United States District Court for the Northern District of California, civil action number C-03-4999, on behalf of all persons or entities who purchased or otherwise acquired Gilead Sciences, Inc. ("Gilead" or the "Company") securities (Nasdaq:GILD) during the class period: July 14, 2003 and October 28, 2003, inclusive. The Complaint names Gilead Sciences, Inc., John C. Martin, John F. Milligan, Mark L. Perry, Norbert W. Bischofberger, Anthony Carraciolo, and William A. Lee as defendants.